Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Independence Blue CrossMedicare Advantage · Billing Codes · Pharmacy · Oncology, Hematology, Pediatrics +1 moreLow impact

MA08.085k, Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)

Act
by Jan 1, 2026
Effective date
Jan 1, 2026
Identified
Jun 19, 2026

Summary

Independence Blue Cross reissued MA08.085k with no substantive changes to coverage for Rylaze (asparaginase erwinia chrysanthemi recombinant-rywn). The terminated HCPCS code J9019 (Erwinaze) has been removed from the policy, and only the active code J9021 (Rylaze) now appears. Coverage criteria for ALL, lymphoblastic lymphoma, and NK/T-cell lymphomas remain unchanged, requiring hypersensitivity to E. coli-derived asparaginase and absence of specified contraindications.

Get alerts when payers change rules like this one

We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.

Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.

What to do

by Jan 1, 2026 · 5 steps
01Billing team must update billing system to remove or deactivate HCPCS code J9019 (Injection, asparaginase [Erwinaze], 1,000 IU) from all claim submission workflows and templates.
02Ensure that only J9021 (Injection, asparaginase, recombinant [Rylaze], 0.1 mg) is used for Rylaze claims submitted to Independence Blue Cross Medicare Advantage plans.
03Verify that prior authorization processes require documentation of E.
04coli-derived asparaginase hypersensitivity and absence of contraindications (serious hypersensitivity history, pancreatitis history, hemorrhagic/thrombotic events, or severe hepatic impairment) before claim submission.
05No immediate action required if this date has already passed; verify compliance during next policy audit.

Codes mentioned

J9021J9019

Original notice

MA08.085k, Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)
medpolicy.ibx.com · Always check the source before changing claims.
View original ↗

Related changes

See all Independence Blue Cross changes →
MA08.085k, Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)MediumEffective Jan 1, 2026 · Pharmacy08.01.35k, Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)MediumEffective Jan 1, 2026 · Pharmacy08.01.35k, Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)MediumEffective Jan 1, 2026 · PharmacyMA08.085i, Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)MediumEffective Jan 1, 2025 · PharmacyBrowse every Independence Blue Cross change in the policy list

Related policy hubs

Independence Blue Cross policiesOncologyHematologyPediatricsPharmacyCode J9021Code J9019

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account